Abstract
Single-Dose Ad26.COV2.S Vaccine—Room for Improvement
Highlights
Compared with the messenger RNA–based vaccines, the Ad26.COV2.S vaccine (Johnson & Johnson) has been administered less often; concurrently, there are fewer data on vaccine effectiveness (VE) for this vaccine
In terms of VE, 2 studies have shown that the effectiveness of the Ad26.COV2.S vaccine is stable over time, with a moderate decrease in effectiveness for individuals older than 75 years.[5,6]
What is becoming more clear with time is that the single-dose regimen of the Ad26.COV2.S vaccine seems to be inferior to the messenger RNA (mRNA)-based vaccines in terms of VE
Summary
Compared with the messenger RNA (mRNA)–based vaccines, the Ad26.COV2.S vaccine (Johnson & Johnson) has been administered less often; concurrently, there are fewer data on VE for this vaccine. The study by CorchadoGarcia et al[1] is part of a growing body of work surrounding humoral responses to a single dose of the Ad26.COV2.S vaccine and VE.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
